



UNICHEM
LABORATORIES LTD.

November 12, 2022

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no.
C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Code: 506690

Scrip Code: 506690

Dear Sir/Madam

Sub.: Financial Results for Second quarter and Six months ended September 30, 2022 published in newspapers on November 12, 2022 .

Pursuant to Regulation 47 of the Listing Regulations, please find attached copies of the Financial Results for the second quarter and six months ended September 30, 2022 published in the following newspapers on November 12, 2022 .

1. Mumbai edition of Business Standard
2. Mumbai edition of Sakal

This is for your information and record.

Thanking you,

For UNICHEM LABORATORIES LIMITED

PRADEEP BHANDARI
Head- Legal & Company Secretary



Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel. +91-44-28290956 Website : www.apollohospitals.com

Email: investor.relations@apollohospitals.com,

**Extract of Statement of Unaudited Consolidated Financial Results for the Three and Six Months Ended September 30, 2022**

(Rs. in Lakhs, except per share data)

| Particulars | Three months ended 30/09/2022 | Preceding Three months ended 30/06/2022 | Corresponding Three months ended 30/09/2021 | Year to date figures for current period ended 30/09/2022 | Year to date figures for previous period ended 30/09/2021 | Previous year ended 31/03/2022 |
|--|------------------------------------|---|---|--|---|--------------------------------|
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| | Total Income from Operations (net) | 425107 | 379560 | 371707 | 804667 | 747728 |
| Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items) | 32707 | 25428 | 38299 | 58135 | 68811 | 129127 |
| Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items) | 32707 | 25428 | 38299 | 58135 | 98222 | 158538 |
| Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items) | 21284 | 32378 | 26741 | 53662 | 76809 | 110836 |
| Total Comprehensive Income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)) | 20653 | 32740 | 25965 | 53393 | 76261 | 109864 |
| Paid up Equity Share Capital (Face value of Rs.5/- each) | | | | | | 7189 |
| Other Equity | | | | | | 554345 |
| Earnings Per Share of Rs. 5/- each | | | | | | |
| Basic | *14.19 | *22.05 | *17.24 | *36.24 | *51.26 | 73.42 |
| Diluted | *14.19 | *22.05 | *17.24 | *36.24 | *51.26 | 73.42 |

* Not Annualised

Notes:

1. The consolidated financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 9, 2022 and November 10, 2022 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three and six months ended September 30, 2022. These consolidated financial results have been extracted from the consolidated financial information.

2. Unaudited financial results of Apollo Hospitals Enterprise Limited (standalone information)

| Particulars | Three months ended 30/09/2022 | Preceding Three months ended 30/06/2022 | Corresponding Three months ended 30/09/2021 | Year to date figures for current period ended 30/09/2022 | Year to date figures for previous period ended 30/09/2021 | Previous year ended 31/03/2022 |
|---|-------------------------------|---|---|--|---|--------------------------------|
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Continuing Operations | | | | | | |
| Revenue from Operations | 171558 | 152969 | 165608 | 324527 | 313880 | 609833 |
| Profit Before Tax | 34559 | 25012 | 25143 | 59571 | 41788 | 85213 |
| Profit after tax for the period | 27919 | 33314 | 16143 | 61233 | 26829 | 57234 |
| Discontinued Operations | | | | | | |
| Revenue from Operations | | | 116712 | | 267912 | 513139 |
| Profit Before Tax | | | 3760 | | 10398 | 14248 |
| Profit after tax for the period | | | 2446 | | 6764 | 9269 |
| Profit after tax for the period from continuing and discontinued operations | 27919 | 33314 | 18589 | 61233 | 33593 | 66503 |
| Total Comprehensive Income for the period (comprising Profit/ (Loss) for the period (after tax) & Other Comprehensive Income (after tax)) | 27315 | 33656 | 18081 | 60971 | 33125 | 66279 |

3. The above is an extract of the detailed format of financial results for the three and six months ended September 30, 2022 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.

4. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ("the Amendment Act"). Accordingly, the Company has recognised provision for income tax for the quarter and six months ended September 30, 2022 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Liability (net) as at April 1, 2022 and accounted tax credit of Rs. 14,659 lakhs relating to the same in the previous quarter.

5. The Company had received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020:

- Apollo Home Healthcare (India) Limited and
- Western Hospitals Corporation Private Limited

Consequent to giving effect to the said Scheme of Amalgamation, the Company had created a provision against loan of Rs. 674 lakhs extended by Western Hospitals Corporation Private Limited to its subsidiary Apollo Lavasa Health Corporation Limited. This provision was disclosed under Exceptional Items in the standalone financial results for the year to date September 30, 2021 and year ended March 31, 2022.

6. The Company in the year ended Mar 31, 2022 reorganised its pharmacy distribution by transferring to Apollo Healthco Limited, a wholly owned subsidiary of the Company.

7. Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs.

The utilisation of the QIP Issue proceeds upto September 30, 2022 is as follows:

| Particulars | Amount in Rs. Lakhs |
|--|---------------------|
| Fees paid to Lead Managers | 1,785.00 |
| Foreclosure of debts | 25,138.00 |
| Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited | 41,000.00 |
| Acquisition of equity stake in Apollo Hospitals North Limited | 27,500.00 |
| Loan given to Apollo Hospitals North Limited | 21,576.00 |

8. The Company has executed definitive agreements on 5th October 2022 in connection with the acquisition of a 60% equity stake in Kerala First Health Services Private Limited ("KFHSL"), which offers quality systems driven Ayurveda medical care services under the "AyurVAID Hospitals" brand through a combination of primary and secondary equity investment with the overall transaction consideration of Rs. 2,640 lakhs.

The primary investment will be used to upgrade existing centres, set up new centres, strengthen enterprise platforms, and for digital health initiatives. Consequent to this acquisition, KFHSL would become a subsidiary of the Company.

9. The Company had invested an amount of Rs. 27,500 lakhs in the equity capital of Apollo Hospitals North Limited (wholly owned subsidiary company) and also provided an unsecured loan amount of Rs. 21,576 lakhs for its expansion activities.

10. Apollo Hospitals North Limited, wholly owned subsidiary of the Company has completed the acquisition of the assets forming part of a 650 bedded potential hospital facility, which was being set up by Nayati Healthcare and Research NCR Private Limited in Gurgaon for a consideration of about Rs 47,587 lakhs (incl Stamp Duty & other incidental charges).

11. The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Speciality Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on April 22, 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from April 22, 2021. The resultant goodwill of Rs. 53,714 lakhs has been presented within the Healthcare segment.

The acquisition date fair value of the existing equity interest in AMSHL compared to its carrying amount resulted in a gain of Rs. 29,411 lakhs, which has been included under exceptional items.

12. On November 12, 2021, Assam Hospitals Limited, a subsidiary company of the Group had acquired 64.42% shareholding in Asclepius Hospitals & Healthcare Private Limited.

Based on the information available at March 31, 2022, the Subsidiary Company determined a preliminary purchase price allocation based on the provisional amounts of the identifiable assets acquired and liabilities assumed, resulting in a provisional goodwill of Rs. 1,153 lakhs as at March 31, 2022, subject to finalisation of the purchase accounting. As at September 30, 2022 on receipt of complete information the purchase accounting is finalised, resulting in increase in the goodwill balance to Rs. 2,795 lakhs.

13. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and have remitted it back to the Revenue Department for reconsideration and disposal. The Revenue Department had issued a show cause notice dated 9 February 2022 seeking explanations as to why the original order needs to be withdrawn for which the subsidiary company had filed a detailed response explaining there were no violations of the conditions relating to the allotment of the land. Based on legal opinion received, the subsidiary company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in their favour.

14. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

Place : Chennai
Date : 10th November, 2022for APOLLO HOSPITALS ENTERPRISE LIMITED
DR. PRATHAP C REDDY
Executive Chairman**MORGANITE CRUCIBLE (INDIA) LIMITED**

CIN:L26920MH1986PLC038607

Registered Office: B-11, MIDC Industrial Area, Waluj, Aurangabad 431 136

Statement of Unaudited Financial Results for the Quarter & Half Year ended September 30, 2022

(Amt INR in Lakhs)

| Sr. No. | Particular | Quarter Ended | | | Half Year Ended | | Year Ended |
|---------|---|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|
| | | 30.09.2022 (Unaudited) | 30.06.2022 (Unaudited) | 30.09.2021 (Unaudited) | 30.09.2022 (Unaudited) | 30.09.2021 (Unaudited) | 31.03.2022 (Audited) |
| 1 | Total Income from operation | 3,907.77 | 4,141.93 | 3,692.26 | 8,049.70 | 7,175.40 | 18,131.58 |
| 2 | Net Profit for the period (before Tax, Exceptional and / or Extraordinary items) | 520.02 | 589.92 | 701.57 | 1,109.94 | 1,312.69 | 5,138.00 |
| 3 | Net Profit for the period before tax (after Exceptional and / or Extraordinary Items) | 520.02 | 589.92 | 701.57 | 1,109.94 | 1,622.69 | 5,448.00 |
| 4 | Net Profit for the period after tax (after Exceptional and / or Extraordinary items) | 390.75 | 432.89 | 525.86 | 823.64 | 1,198.91 | 4,339.34 |
| 5 | Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 386.80 | 447.32 | 526.97 | 834.11 | 1,195.93 | 4,362.74 |
| 6 | Equity Share Capital | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 |
| 7 | Other Equity (Reserves excluding revaluation reserves) | - | - | - | - | - | 11,975.47 |
| 8 | Earnings Per Share (of Rs. 5/- each) (for continuing operations) Basic & Diluted | 6.98 | 7.73 | 9.39 | 14.71 | 21.41 | 77.49 |

1. The above financial results of Morganite Crucible (India) Limited ("The Company") were reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on 10 November 2022. The results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 - Interim financial reporting prescribed under section 133 of the companies act, 2013, read with relevant rules issues thereunder as amended from time to time.

2. The Statutory Auditors of the Company have conducted review of quarterly and half year ended financial results of the Company for the quarter and half year ended 30 September 2022.

3. The Board of Directors at its meeting held on Thursday, 10 November 2022 have declared an Interim Dividend of ₹ 9.00 per equity share. The total interim dividend amounts to ₹ 504 lakh and will be paid to the equity shareholders of the Company whose names appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on Wednesday, 23 November 2022 being the Record Date fixed for the purpose.

4. The Financial Results have been made available to the Stock Exchange where the Company's securities are listed and are posted on the Company's website (www.morganmms.com).

For Morganite Crucible (India) Limited
Sd/-Aniruddha Karve
(Director)
DIN: 07180005Place: Aurangabad, India
Date: 10.11.2022**UNICHEM LABORATORIES LTD.**

CIN:L99999MH1962PLC012451

Registered Office: Unichem Bhavan, Prabhath Estate, Off S. V. Road, Jogeshwari (West), Mumbai - 400 102

Website: www.unichemlabs.com; E-mail Id.: shares@unichemlabs.com;

Tel.: (022) 6688 8333

EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022

(₹ lakhs)

| Sr. No. | Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|---------|---|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Total income from operations | 26,563.83 | 24,478.13 | 21,696.73 | 51,041.96 | 41,777.04 | 94,292.66 |
| 2 | Net Profit / (Loss) for the period (before tax and exceptional items) | (4,982.93) | (2,327.91) | (2,658.98) | (7,310.84) | (6,297.28) | (8,674.77) |
| 3 | Net Profit / (Loss) for the period before tax (after exceptional items) | (5,485.17) | (2,327.91) | (2,658.98) | (7,813.08) | (6,297.28) | (8,674.77) |
| 4 | Net Profit / (Loss) for the period after tax (after exceptional items) | (7,546.39) | (2,327.91) | (2,143.32) | (9,874.30) | (4,926.18) | (5,542.96) |
| 5 | Total comprehensive income for the period (comprising of profit / loss) for the period (after tax) and other comprehensive income (after tax) | (3,916.45) | (2,121.75) | (2,361.98) | (6,038.20) | (5,168.44) | (5.76) |
| 6 | Paid-up Equity Share Capital | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 |
| 7 | Other Equity [Reserves excluding Revaluation Reserve] | | | | | | 2,65,795.97 |
| 8 | Earnings per equity share (Face value of ₹ 2/- per share) (not annualized) | | | | | | |
| (a) | Basic | (10.72) | (3.31) | (3.04) | (14.02) | (7.00) | (7.87) |
| (b) | Diluted | (10.72) | (3.31) | (3.04) | (14.02) | (7.00) | (7.87) |

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022

(₹ lakhs)

| Sr. No. | Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|---------|---|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Total income from operations | 32,881.93 | 30,960.83 | 29,066.08 | 63,842.76 | 58,857.34 | 1,26,983.22 |
| 2 | Net Profit / (Loss) for the period (before tax and exceptional items) | (4,223.05) | (2,067.46) | (1,551.20) | (6,290.51) | (2,455.34) | 2,196.89 |
| 3 | Net Profit / (Loss) for the period before tax (after exceptional items) | (4,725.29) | (2,067.46) | (1,551.20) | (6,792.75) | (2,455.34) | 2,196.89 |
| 4 | Net Profit / (Loss) for the period after tax (after exceptional items) | (7,066.63) | (2,336.87) | (1,281.68) | (9,403.50) | (2,430.56) | 3,306.17 |
| 5 | Total comprehensive income for the period (comprising of profit / loss) for the period (after tax) and other comprehensive income (after tax) | (2,933.98) | (1,651.47) | (1,552.37) | (4,585.45) | (2,716.76) | 8,681.22 |
| 6 | Paid-up Equity Share Capital | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 |
| 7 | Other Equity [Reserves excluding Revaluation Reserve] | | | | | | 2,60,432.98 |
| 8 | Earnings per equity share (Face value of ₹ 2/- per share) (not annualized) | | | | | | |
| (a) | Basic | (10.04) | (3.32) | (1.82) | (13.36) | (3.45) | 4.70 |
| (b) | Diluted | (10.04) | (3.32) | (1.82) | (13.36) | (3.45) | 4.68 |

Notes:

1. The standalone financial results for the quarter and half year ended 30th September, 2022 and consolidated financial results for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2022. The statutory auditors have carried out a limited review of the standalone and consolidated financial results. The above is an extract of the detailed format of the unaudited standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated unaudited financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.

2. The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

| Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|-----------------------|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| Total R&D expenditure | 2,957.07 | 2,205.28 | 2,520.04 | 5,162.35 | 5,617.74 | 11,274.10 |

By Order of the Board
For Unichem Laboratories LimitedSD/-
Dr. Prakash A. Mody
Chairman & Managing Director
DIN : 00001285Place: Mumbai
Date: 11th November, 2022

८० तास काम कया

एलॉन मस्क यांचा कर्मचाऱ्यांना सल्ला

सॅनफ्रान्सिस्को, ता. ११ (वृत्तसंस्था) : आगामी दिवस कठीण असल्यामुळे कर्मचाऱ्यांनी घरातून काम करण्याची वेळ बंद करून कार्यालयात कामाला यावे आणि आठवड्याचे ८० तास काम करावे, असा इशारा ट्विटरचे नवे सर्वेसर्वा एलॉन मस्क यांनी बुधवारी (ता. १०) कर्मचाऱ्यांच्या पहिल्या बैठकीत दिला.



कंपनीच्या येथील मुख्यालयात घेतलेल्या बैठकीत त्यांनी अनेक कठोर निर्णयांचे सुतोवाच केले. मस्क यांनी आधी कर्मचाऱ्यांना ई-मेल पाठवून कार्यालयात ४० तास काम करण्याचे आवाहन केले होते व पुढील दिवस कठीण असल्याचा इशारा दिला होता. या इशाराचा या बैठकीत त्यांनी पुनरावलोकन केले व कर्मचाऱ्यांना ८० तास काम करण्यास बजावले.

कर्मचाऱ्यांना अन्य सवलतीदेखील फार कमी मिळतील, असेही त्यांनी सुनावले.

घरून काम करण्याची कर्मचाऱ्यांना मिळणारी सोय बंद करण्याचेही त्यांनी समर्थन केले. यासंदर्भातील कर्मचाऱ्यांचा प्रसाला उत्तर देताना मस्क चांगलेच भडकले होते, असे काही कर्मचाऱ्यांनी ट्विट करून सांगितले आहे. यापुढे आपल्याला अत्यंत कठोरपणे मेहनत करावी लागणार आहे, तुम्ही ते करू शकत नसाल तर तुम्हाला ट्विटरमध्ये काहीही स्थान राहणार नाही, असेही मस्क यांनी स्पष्ट केले आहे.

मुंबईत पोटच्या मुलाला आईने विकले

मुंबई, ता. ११ : एक दिवसाच्या रात्री बेड्या ठोकल्या. पोलिसांनी मुलीला विकण्याचा डाव उघडून दिलेल्या माहितीनुसार, मुलाची खोदी लावत पोलिसांनी बाळाची सुबक करणारी महिला ही पेशाने नर्स आहे; सुटका केली आहे. या प्रकरणी बाळाची खोदी करणाऱ्या नर्ससह आरोपी आई असून ती बेरोजगार आहे. पोलिसांनी आईला गुरुवारी (ता. ११)

टाटा एआयजी जनरल इन्शुरन्स कंपनी लिमिटेड
 नोंदणीकृत कार्यालय : पेनिन्सुला बिझनेस पार्क, टॉप ए, १५ वा मजला, गणपतराव कवय मार्ग, लोअर पोर, मुंबई - ४० ००१३
 ब्र. : ०२२ - ६६६९१७६१ / फॅक्स : ०२२ - ६६६४६४६४
 ई-मेल : secretarial@tataig.com वेबसाइट : www.tataig.com
 सीआयएन : U85110MH2000PLC128425

सूचना
 याद्वारे सूचना देण्यात येत आहे की, कंपनीद्वारे जारी व दि. १९ डिसेंबर, २०२१ रोजी विमोचनयोग्य असलेल्या दि. १९ डिसेंबर, २०२२ रोजीनुसार अप्रतिभूत, दुय्यम, सूचिबद्ध, विमोचनयोग्य, बिगारपरीवर्तनीय पूर्णतः प्रदानित डिसेंबर देय ८.८५ टक्के (८.८५%) दराने वार्षिक व्याज प्राप्त करण्यासाठी पात्र असलेल्या कंपनीच्या कर्जरोखे डिसेंबरधारकांच्या पात्रतेच्या निश्चितीसाठी शनिवार, दि. ४ डिसेंबर, २०२२ ही तारीख नोंद दिनांक म्हणून निश्चित करण्यात आली आहे.

कर्जरोखेधारकांनी कृपया कंपनीचे रजिस्ट्रार व ट्रान्सफर एजंट, एनएसडीएल डेटाबेस मॅनेजमेंट लिमिटेड यांना, लागू असल्यानुसार कर्जरोखेधारकांचे संपूर्ण नाव, पत्ता, क्लायन्ट आयडी व डीपी आयडी लागू असल्याप्रमाणे नमूद करून सर्व भविष्यकालीन पत्रव्यवहार, कर्जरोखेधारकील व्याजासंदर्भात तसेच पत्त्यातील बदलांची सूचना द्यावी.

टाटा एआयजी जनरल इन्शुरन्स कंपनी लिमिटेड
 सही/-
 आशिष शर्मा
 कंपनी सचिव

ठिकाण : मुंबई
 दिनांक : १२.११.२०२२

Pfizer
फायझर लिमिटेड
 CIN: L24231MH1950PLC008311
 द कॉर्पोरेट, 1802/1901, प्लॉट क्र. C-70, जी- ब्लॉक, गॅरेज कुर्ला कॉम्प्लेक्स, गॅरेज (E), मुंबई 400 051
 कूरुवनी: +91 22 6693 2000 फॅक्स: +91 226254 0274
 ई-मेल आयडी: contactus.india@pfizer.com वेबसाइट: www.pfizeritd.co.in

३० सप्टेंबर २०२२ रोजी संपलेल्या तिमाही आणि अर्ध वर्षासाठी अलेखापरिचित आर्थिक परिणामांचा विधानाचा उतारा
 (प्रति शेअर कमाई व्यतिरिक्त ₹ कोटीमध्ये)

| तपशील | ३० सप्टेंबर २०२२ रोजी संपलेली तिमाही | ३० सप्टेंबर २०२२ रोजी संपलेली चालू वर्षासाठी तारीख निहाय वर्ष | ३० सप्टेंबर २०२१ रोजी संपलेली संवधित ३ महिने |
|--|--------------------------------------|---|--|
| १. एकूण उत्पन्न | ६६९.७९ | ९२७२.६३ | ६५९.२९ |
| २. तिमाही / कालवधीसाठी निव्वळ नफा (कर पूर्व, अपवादामक आणि/किंवा असाधारण वस्तू) | २२६.३० | ४०६.०२ | ९७४.९६ |
| ३. तिमाही / कालवधीसाठी करपूर्वी निव्वळ नफा (अपवादामक आणि/किंवा असाधारण वस्तू पक्षात) | ४९५.२२ | ४५८.६९ | ९७४.९६ |
| ४. तिमाही / कालवधीसाठी कर पक्षात निव्वळ नफा (अपवादामक आणि/किंवा असाधारण आयटम पक्षात) | ३९९.०७ | ३४३.६२ | ९४२.९५ |
| ५. तिमाही / कालवधीसाठी एकूण सर्वसमावेशक उत्पन्न (या कालवधीसाठी समावेशक नफा (कर पक्षात) आणि इतर सर्वसमावेशक उत्पन्न (कर पक्षात)) | ३९०.८७ | ३४३.२३ | ९४३.९० |
| ६. इन्विस्टी शेअर कॅपिटल (समभाग मांडवळ) | ४४.७५ | ४४.७५ | ४४.७५ |
| ७. रिझर्व्स अर्थात राखीव (पुनर्मुल्यांकन राखीव वगळून) मागील वर्षाच्या तालबंदीत दाखलव्याप्रमाणे | - | - | - |
| ८. प्रति शेअर कमाई (₹/- प्रत्येकी) (वार्षिक नाही) * | ६७.९९* | ७५.९९* | ३९.२५* |
| ९. डायल्युटेड : | ६७.९९* | ७५.९९* | ३९.२५* |

टीप :
 १. उपरोक्त उतारा हा SEBI (सूचीबद्ध दायित्व आणि प्रकटीकरण आवश्यकता) विनियम, २०१५ च्या नियमन ३३ अंतर्गत स्टॉक एक्सचेंजमध्ये दाखल केलेल्या त्रैमासिक आर्थिक निकालांच्या तपशीलवार स्वरूपाचा एक उतारा आहे. त्रैमासिक आर्थिक निकालांचे संपूर्ण स्वरूप स्टॉक एक्सचेंजच्या पुढील वेबसाइट्स www.bseindia.com आणि www.nseindia.com आणि www.pfizeritd.co.in वर उपलब्ध आहे. तसेच कंपनीच्या www.pfizeritd.co.in या वेबसाइटवरही उपलब्ध आहे

फायझर लिमिटेडसाठी
 ए. श्रीधर
 व्यवस्थापकीय संचालक

११ नोव्हेंबर २०२२

राजीव यांच्या मारेकऱ्यांची मुक्तता

पान १ वरून येथे धनु नावाच्या महिला आत्मघातकी हल्लेखोराणे हत्या केली होती. निवडणूक सभेवेळी लिबरेशन टायगर ऑफ तमिल इलमची (एलटीटीई) महिला दहशतवादी धनु (तेनमोजी राजलम) हिने राजीव गांधींना फुलांचा हार घातल्यानंतर त्यांच्या पायाला स्पर्श केला आणि खाली वाकून कपरेला बांधलेल्या स्फोटकांचा स्फोट केला. हा स्फोट एवढा जोरदार होता की अनेकांचे तुकडे झाले. राजीव गांधी आणि हल्लेखोर धनु यांच्यासह १६ जणांचा जागीच मृत्यू झाला, तर ४५ जण गंभीर जखमी झाले होते. राजीव यांनी त्यांच्या कार्याळात श्रीलंकेत शांतिसेना पाठवली होती. या शांतिसेनाला लिबरेशन टायगर ऑफ तमिल इलम या तमिळ बंडखोरांचा विरोध होता. त्यातूनच हा आत्मघातकी हल्ला घडवून आणला होता.

या प्रकरणी नलिनी, रामचंद्रन, संधान, मुगन, पेरारीवलन, रॉबर्ट पायस आणि जयकुमार या रोपिंना जमरटोपेची शिक्षा देण्यात आली होती. घटनेच्या कालम १४२ मधील विशेषाधिकाराचा वापर करत सर्वोच्च न्यायालयाने पेरारीवलनची सुमारे ३० वर्षांनंतर सुटका करण्याचे आदेश यावर्षी २१ मे रोजी दिले होते.

सोनियांनी नलिनीला केले होते माफ

राजीव गांधी यांच्या हत्येप्रकरणी नलिनीला अटक झाली तेव्हा ती गर्भवती होती. तिला गरोदर होऊन दोन महिने झाले होते. त्यानंतर सोनिया गांधींनी नलिनीला माफ केले. नलिनीच्या चुकीची शिक्षा अद्याप जगतात न आलेल्या एका निष्पाप बाळाला कशी दिली जाऊ शकते, असे त्या म्हणाल्या होत्या.

UNICHEM LABORATORIES LTD.
 CIN:L99999MH1962PLC012451
 Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai - 400 102
 Website: www.unichemlabs.com; E-mail Id: shares@unichemlabs.com;
 Tel.: (022) 6688 8333

EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2022

| Sr. No. | Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|---------|---|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Total income from operations | 26,563.83 | 24,478.13 | 21,696.73 | 51,041.96 | 41,777.04 | 94,292.66 |
| 2 | Net Profit / (Loss) for the period (before tax and exceptional items) | (4,982.93) | (2,327.91) | (2,658.98) | (7,310.84) | (6,297.28) | (8,674.77) |
| 3 | Net Profit / (Loss) for the period before tax (after exceptional items) | (5,485.17) | (2,327.91) | (2,658.98) | (7,813.08) | (6,297.28) | (8,674.77) |
| 4 | Net Profit / (Loss) for the period after tax (after exceptional items) | (7,546.39) | (2,327.91) | (2,143.32) | (9,874.30) | (4,928.18) | (5,542.96) |
| 5 | Total comprehensive income for the period (comprising of profit / loss for the period (after tax) and other comprehensive income (after tax)) | (3,916.45) | (2,121.75) | (2,361.98) | (6,038.20) | (5,168.44) | (5.76) |
| 6 | Paid-up Equity Share Capital | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 |
| 7 | Other Equity [Reserves excluding Revaluation Reserve] | - | - | - | - | - | 2,65,795.97 |
| 8 | Earnings per equity share (Face value of ₹ 2/- per share) (not annualized) | (10.72) | (3.31) | (3.04) | (14.02) | (7.00) | (7.87) |
| | (a) Basic | (10.72) | (3.31) | (3.04) | (14.02) | (7.00) | (7.87) |
| | (b) Diluted | (10.72) | (3.31) | (3.04) | (14.02) | (7.00) | (7.87) |

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2022

| Sr. No. | Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|---------|---|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Total income from operations | 32,881.93 | 30,960.83 | 29,066.08 | 63,842.76 | 58,857.34 | 1,26,983.22 |
| 2 | Net Profit / (Loss) for the period (before tax and exceptional items) | (4,223.05) | (2,067.46) | (1,551.20) | (6,290.51) | (2,455.34) | 2,196.89 |
| 3 | Net Profit / (Loss) for the period before tax (after exceptional items) | (4,725.29) | (2,067.46) | (1,551.20) | (6,792.75) | (2,455.34) | 2,196.89 |
| 4 | Net Profit / (Loss) for the period after tax (after exceptional items) | (7,066.63) | (2,336.87) | (1,281.68) | (9,403.50) | (2,430.56) | 3,306.17 |
| 5 | Total comprehensive income for the period (comprising of profit / loss for the period (after tax) and other comprehensive income (after tax)) | (2,933.98) | (1,651.47) | (1,552.37) | (4,585.45) | (2,716.76) | 8,681.22 |
| 6 | Paid-up Equity Share Capital | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 | 1,408.12 |
| 7 | Other Equity [Reserves excluding Revaluation Reserve] | - | - | - | - | - | 2,60,432.98 |
| 8 | Earnings per equity share (Face value of ₹ 2/- per share) (not annualized) | (10.04) | (3.32) | (1.82) | (13.36) | (3.45) | 4.70 |
| | (a) Basic | (10.04) | (3.32) | (1.82) | (13.36) | (3.45) | 4.70 |
| | (b) Diluted | (10.04) | (3.32) | (1.82) | (13.36) | (3.45) | 4.68 |

Notes:

- The standalone financial results for the quarter and half year ended 30th September, 2022 and consolidated financial results for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2022. The statutory auditors have carried out a limited review of the standalone and consolidated financial results. The above is an extract of the detailed format of the unaudited standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated unaudited financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.
- The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

| Particulars | Quarter ended 30 th Sep'22 | Quarter ended 30 th Jun'22 | Quarter ended 30 th Sep'21 | Six months ended 30 th Sep'22 | Six months ended 30 th Sep'21 | Year ended 31 st Mar'22 |
|-----------------------|---------------------------------------|---------------------------------------|---------------------------------------|--|--|------------------------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| Total R&D expenditure | 2,957.07 | 2,205.28 | 2,520.04 | 5,162.35 | 5,617.74 | 11,274.10 |

By Order of the Board
 For Unichem Laboratories Limited
 SD/-
 Dr. Prakash A. Mody
 Chairman & Managing Director
 DIN : 0001285

Place: Mumbai
 Date: 11th November, 2022

J. B. CHEMICALS & PHARMACEUTICALS LIMITED
 Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office: Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor
 Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022-2431 5331 / 2431 5334
 CIN : L24390MH1976PLC019380 Website: www.jbpharma.com E-mail : secretarial@jbpharma.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30/09/2022
 (₹ In lakhs)

| Sl. No. | Particulars | Quarter ended | | | Half year ended | | Year ended 31/03/2022 |
|---------|---|---------------|------------|------------|-----------------|------------|-----------------------|
| | | 30/09/2022 | 30/06/2022 | 30/09/2021 | 30/09/2022 | 30/09/2021 | |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | |
| 1 | Total Income from operations | 80,944 | 78,481 | 59,301 | 159,425 | 119,900 | 242,424 |
| 2 | Net Profit for the period before tax | 14,983 | 14,174 | 12,943 | 29,157 | 28,730 | 50,490 |
| 3 | Net Profit for the period after tax | 11,108 | 10,520 | 9,789 | 21,628 | 21,695 | 38,604 |
| 4 | Total Comprehensive Income for the period after tax | 9,940 | 10,570 | 9,060 | 20,510 | 21,300 | 39,005 |
| 5 | Equity Share Capital | 1,547 | 1,546 | 1,546 | 1,547 | 1,546 | 1,546 |
| 6 | Reserves | - | - | - | - | - | 211,867 |
| 7 | Earnings per share (EPS) (of ₹ 2/- each) | | | | | | |
| | Basic: | *14.37 | *13.59 | *12.65 | *27.96 | *28.03 | 49.86 |
| | Diluted: | *14.26 | *13.56 | *12.63 | *27.75 | *28.01 | 49.82 |

* Not Annualised
Notes
 1. The key performance figures of standalone unaudited financial results for the quarter and six months ended 30/09/2022 are as under:

| Sl. No. | Particulars | Quarter ended | | | Half year ended | | Year ended 31/03/2022 |
|---------|--------------------------------------|---------------|------------|------------|-----------------|------------|-----------------------|
| | | 30/09/2022 | 30/06/2022 | 30/09/2021 | 30/09/2022 | 30/09/2021 | |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | |
| 1 | Total Income from operations | 73,996 | 71,613 | 52,673 | 145,609 | 107,303 | 218,988 |
| 2 | Net Profit for the period before tax | 13,220 | 13,701 | 11,766 | 26,921 | 27,048 | 47,129 |
| 3 | Net Profit for the period after tax | 9,772 | 10,129 | 8,840 | 19,901 | 20,371 | 36,100 |

2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2022.
 3. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites viz. www.bseindia.com and www.nseindia.com and the Company's website www.jbpharma.com.

For J. B. Chemicals & Pharmaceuticals Ltd.
 Ranjit Shahani
 Chairman

Date : November 11, 2022
 Place : Mumbai